• 16.05.2018, 08:02:11
  • /
  • OTE0002

BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

Stockholm (ots/PRNewswire) - BioLamina and collaborators have
partnered with Novo Nordisk A/S (Novo Nordisk), a Danish
multinational pharmaceutical company, allowing Novo Nordisk to
develop novel stem cell based therapies based on Biolaminins, human
recombinant laminin cell culture matrices, developed and produced by
BioLamina.

Novo Nordisk have announced today that they are increasing their
commitment to cell therapies, including areas outside of diabetes.
The three cell therapy projects they have licensed are all based on
BioLamina technology. These projects aim to treat Parkinson's
disease, heart failure and loss of vision, all severe chronic
conditions.

Malin Parmar's research group at Lund University and Karl
Tryggvason's research group at Duke-NUS in Singapore have developed
potential cell therapies based on BioLamina's unique Biolaminin
matrices. Both groups have signed research and potential licensing
agreements with Novo Nordisk with the aim to develop these projects
further together with Novo Nordisk, enabling a translation of cell
therapy pre-clinical studies, to clinical trials and eventually
towards patient treatments.

The timing for these licensing agreements coincides well with the
launch of BioLamina's first cell therapy grade product a couple of
weeks ago, assuring cell therapy developers worldwide that
Biolamina's products can be used all the way from the bench to
bedside. There is an ongoing trend that researchers using embryonic
stem cell or induced pluripotent based protocols want to use
BioLamina products in their product development to make their
processes more robust and reproducible.

"There is a high demand for BioLamina's products in the development
of safe and robust cell-based therapies," says Kristian Tryggvason,
CEO for BioLamina, and continues "It is really intriguing to see how
Biolaminins are being part of building new therapies and can help
contribute treating many people in the future."

ABOUT BIOLAMINA AB

BioLamina commercializes innovations based on research from the Karl
Tryggvason laboratory at Karolinska Institute and Duke-NUS solving
technical problems within culturing of embryonic stem cells and other
types of primary cells. Many of the products manufactured and sold by
BioLamina are based on human recombinant proteins called laminins.
The laminins provide cells with an environment mimicking their
natural location in the cell culture dish. Different laminin isoforms
are expressed in different tissues in the body, hence many different
cell types can thrive on laminins. Laminins and other innovations
together solve many of the technical problems in research such as
reproducibility and low cell quality and therefore help the
development of new cell therapies. BioLamina was founded in 2009.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

Bei Facebook teilen.
Bei X teilen.
Bei LinkedIn teilen.
Bei Xing teilen.
Bei Bluesky teilen

Stichworte

Channel